From March 1st, 2020, Laboratorium Ofichem is the prime contractor for the analysis of medicinal cannabis on behalf of Bureau Medicinale Cannabis (BMC). The company will work together with Brightlabs on this project. The two pharmaceutical companies join forces to test the Dutch medicinal cannabis in compliance with the high-quality requirements and applicable standards. Therefore, this arrangement determines whether a batch of medicinal cannabis is approved and made available for both the local and international markets, which will be done within the frameworks as drawn up by BMC.
Since 2013 cannabis has been grown in the Netherlands for medical purposes. The BMC is the public authority that determines the allowable quantity of medicinal cannabis produced and according to which guidelines this occurs, under the international regulations (Single Convention on Narcotic Drugs of 1961). BMC furthermore is responsible for the supply and export of medicinal cannabis. They ensure high-quality is guaranteed during production and delivery.
The directors of both laboratories say they are pleased the call for tender was awarded to them: “It is with great satisfaction that we apply our broad knowledge in the analysis of pharmaceutical substances, for an important raw material such as medicinal cannabis. In this instance, it feels extra special, as this tender is awarded by the government, after an extensive selection.”
The laboratories have validated their analysis methods to guarantee a consistent standard. Laboratorium Ofichem and Brightlabs remain the frontrunners in the reliable analysis of cannabis, as the sole party in the Netherlands that tests medicinal cannabis on behalf of the government.
For more information:
Ofichem Group
Heembadweg 5, 9561 CZ, Ter Apel, The Netherlands
+31 (0)599 583 433
[email protected]
ofichem.com
Brightlabs
St. Jansweg 20, 5928 RC Venlo, The Netherlands
+31 (0)77-77 03 374
[email protected]
brightlabs.nl